How to Outpace Your Competition: Interview with Contraline CEO Kevin Eisenfrats

05/01/24 • 27 min

Medsider: Learn from Medtech and Healthtech Founders and CEOs

In this episode of Medsider Radio, we had a fun conversation with Kevin Eisenfrats, CEO of Contraline. Kevin and his team are developing ADAM, a novel, long-lasting, reversible male contraceptive.

Kevin is a first-time entrepreneur and nanomedical engineer from the University of Virginia (UVA) and has been working on contraceptive technologies since his undergrad years. He has amassed over 50 patents in contraceptive drugs, medical devices, and biomaterials. In 2017, he was honored with a place among the Forbes 30 Under 30 in Healthcare.

In this interview, Kevin offers insights on how to move swiftly through clinical trials, community-building in medtech, creative fundraising efforts, and the importance of executing thorough scientific and market research.

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!

We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!

In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd rather read than listen, here's a link to the full interview with Kevin Eisenfrats.

In this episode of Medsider Radio, we had a fun conversation with Kevin Eisenfrats, CEO of Contraline. Kevin and his team are developing ADAM, a novel, long-lasting, reversible male contraceptive.

Before we dive into the discussion, I wanted to mention a few things:

Lastly, if you'd rather read than listen, here's a link to the full interview with Kevin Eisenfrats.

Previous Episode

Two Important Customers — FDA and CMS: Interview with Procyrion CEO Dr. Eric Fain

In this episode of Medsider Radio, we had an insightful discussion with Dr. Eric Fain, CEO and President of Procyrion — a startup developing an advanced percutaneous mechanical circulatory support device for patients with chronic heart failure.

Eric began his career at Ventritex, a startup focused on implantable defibrillators. Over the next 30 years, and through the company’s acquisition by St. Jude Medical, he has held a number of leadership roles overseeing global sales, marketing, R&D, and clinical, eventually becoming the Group President via St. Jude’s exit to Abbott.

In this interview, Eric shares his expertise in managing startup finances, attracting investors through strategic planning, drawing up clear clinical roadmaps, and engaging with payers to catalyze commercialization.

Before we dive into the discussion, I wanted to mention a few things:

Lastly, if you'd rather read than listen, here's a link to the full interview with Dr. Eric Fain.

Next Episode

How to Compete with Industry Goliaths: Interview with Butterfly Network CEO Joe DeVivo

In this episode of Medsider Radio, we sat down with medtech veteran Joe DeVivo, President and CEO of Butterfly Network. Butterfly iQ3 is the startup's latest chip-powered, hand-held ultrasound device with superior image quality and ultrafast scan times.
Joe is a proven executive with 35 years of business leadership experience, including 22 years in the medical device industry spanning small start-up companies to multi-billion-dollar organizations. He has acquired and fully integrated eight companies, engineered four business turnarounds, and delivered five company exits.

In this interview, Joe shares insights on why a lean start in commercialization is better than a high-burn, high-risk approach, the difference between your company being sold and being purchased, and best practices for managing M&A transactions.

Before we dive into the discussion, I wanted to mention a few things:

Lastly, if you'd rather read than listen, here's a link to the full interview with Joe DeVivo.